GLP1R and pancreatitis: In addition, it was observed that use of any GLP-1 RA was associated with the risk of pancreatitis, and the signal strength of pancreatitis was ranked as follows: liraglutide (ROR, 32.67; 95% CI, 29.44–36.25) > semaglutide (ROR, 19.10, 95% CI, 17.26–21.13) > dulaglutide (ROR, 12.63; 95% CI, 11.76–13.56) > lixisenatide (ROR, 6.78; 95% CI 4.26–10.80) > exenatide (ROR, 4.91; 95% CI, 4.12–5.85).